You are currently viewing a new version of our website. To view the old version click .
  • Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.

Journal of Market Access & Health Policy, Volume 2, Issue 1

January 2014 - 16 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (16)

  • Article
  • Open Access
16 Citations
614 Views
13 Pages

Background: Drug repurposing is a group of development strategies employed in order to overcome some of the hurdles innate to drug research and development. Drug repurposing includes drug repositioning, reformulation and combination. Objective: This...

  • Article
  • Open Access
47 Citations
823 Views
16 Pages

Background: Repurposing has become a mainstream strategy in drug development, but it faces multiple challenges, amongst them the increasing and ever changing regulatory framework. This is the second study of a series of three-part publication project...

  • Article
  • Open Access
40 Citations
466 Views
5 Pages

Are Payers Treating Orphan Drugs Differently?

  • Joshua P. Cohen and
  • Abigail Felix

Background: Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launches in recent years. In this ar...

  • Communication
  • Open Access
363 Views
4 Pages

At the present time, developed countries are making a huge financial effort to support neuroscience research programs, particularly in the fields of advanced research and treatment of brain diseases and mental disorders. A part of this financial supp...

  • Communication
  • Open Access
34 Citations
520 Views
4 Pages

Quantitative patient preferences are a method to involve patients in regulatory benefit-risk assessment. Assuming preferences can be elicited, there might be multiple advantages to their use. Legal, methodological and procedural issues do however imp...

  • Perspective
  • Open Access
4 Citations
386 Views
8 Pages

Background: Recently, collaboration between regulators and payers was set up and was mainly focused on evidence generation along product clinical development. However, neither the regulatory path nor the new active substance status (NASs) was conside...

  • Article
  • Open Access
7 Citations
452 Views
15 Pages

Novel Methodology for Pharmaceutical Expenditure Forecast

  • Anne-Lise Vataire,
  • Laurent Cetinsoy,
  • Samuel Aballéa,
  • Cécile Rémuzat,
  • Duccio Urbinati,
  • Åsa Kornfeld,
  • Olfa Mzoughi and
  • Mondher Toumi

Background and objective: The value appreciation of new drugs across countries today features a disruption that is making the historical data that are used for forecasting pharmaceutical expenditure poorly reliable. Forecasting methods rarely address...

  • Article
  • Open Access
12 Citations
431 Views
12 Pages

Using Multicriteria Decision Analysis during Drug Development to Predict Reimbursement Decisions

  • Paul Williams,
  • Josephine Mauskopf,
  • Jake Lebiecki and
  • Anne Kilburg

Background: Pharmaceutical companies design clinical development programs to generate the data that they believe will support reimbursement for the experimental compound. Objective: The objective of the study was to present a process for using multic...

  • Article
  • Open Access
9 Citations
512 Views
9 Pages

EU Pharmaceutical Expenditure Forecast

  • Duccio Urbinati,
  • Cécile Rémuzat,
  • Åsa Kornfeld,
  • Anne-Lise Vataire,
  • Laurent Cetinsoy,
  • Samuel Aballéa,
  • Olfa Mzoughi and
  • Mondher Toumi

Background and Objectives: With constant incentives for healthcare payers to contain their pharmaceutical budgets, forecasting has become critically important. Some countries have, for instance, developed pharmaceutical horizon scanning units. The ob...

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
J. Mark. Access Health Policy - ISSN 2001-6689